Pfizer to acquire blood cancer drugmaker Trillium for €1.93bn

Pfizer’s oncology portfolio now includes 24 approved drugs

Drugs are expected to become another important backbone of immunotherapy for multiple types of cancer. File picture: Scott Eisen/Bloomberg

Pfizer, maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26bn (€1.93bn).

Pfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said in a statement. The price represents a 118% premium to the stock’s 60-day weighted average price.